Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Biomedicine (Taipei). 2014;4:26. Epub 2014 Nov 22.

Lyophilized particles and ethanolic extracts of Antrodia cinnamomea mycelia suppress the tumorigenicity of head and neck cancer cells in vivo.

Author information

1
Institute of Oral Biology, National Yang-Ming University, No. 155, Section 2, Li-Nong Street, 112 Taipei, Taiwan.
2
Department of Biotechnology, Hungkuang University, 433 Taichung, Taiwan.
3
Grape King Inc, 320 Taoyuan County, Taiwan.
4
Institute of Biomedical Sciences, Academia Sinica, 115 Taipei, Taiwan.
5
Institute of Oral Biology, National Yang-Ming University, No. 155, Section 2, Li-Nong Street, 112 Taipei, Taiwan ; Graduate Institute of Chinese Medical Science and Institute of Medical Science, China Medical University, 404 Taichung, Taiwan ; Genome Research Center, National Yang-Ming University, 112 Taipei, Taiwan ; Department of Dentistry, Taipei Veterans General Hospital, 112 Taipei, Taiwan.

Abstract

Head and neck cancer (HNC) is one of the most common forms of cancer in Taiwan. In addition, head and neck cancer cells (HNCs) are highly tumorigenic and resistant to conventional therapy. Therefore, development of new therapeutic regimens that are adjuvant to conventional treatments would benefit future head and neck cancer therapy. In this study, we found that the lyophilized particles and ethanolic extracts of Antrodia cinnamomea mycelia inhibited the tumor growth of HNCs by xenograft assay in vivo. Moreover, administration of lyophilized particles or ethanolic extracts to nude mice did not cause significant side effects. Our study revealed that the Antrodia cinnamomea mycelia extract (ACME) efficiently inhibited the tumorigenicity of HNCs without causing organ failure. Furthermore, it showed that ACME may work as a novel drug candidate for alternative treatments for head and neck cancer.

KEYWORDS:

Antrodia cinnamomea;; Head and neck cancer

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center